Avillion II (AZ)

http://www.avillionllp.com/
Tags:DevelopmentDrugFinanceFinTechTechnologyTime
Avillion is focused on clinical co-development and financing of late-stage therapeutics. The company has formed a deal with AstraZeneca to develop and finance a potential asthma therapy through clinical trials to regulatory approval. PT027 is a fixed dose combination of two drugs that are being co-administered for the first time via a new inhaler technology. The drugs comprise an anti-inflammatory steroid, budesonide, and a bronchodilator, albuterol, a short-acting beta-2 agonist. The inhaler is designed and manufactured by Pearl Therapeutics, a subsidiary of AZ.
Location: United Kingdom, London

Investors 1

Mentions in press and media 1

DateTitleDescriptionCategoryAuthorSource
28.01.2013Avillion R...Avillion LLP, a London, UK-bas...funding U...-finsmes.co...